Common-Size Income Statement
Paying users area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Income Statement
- Analysis of Profitability Ratios
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get 1-month access to Bristol-Myers Squibb Co. for $19.99, or
get full access to the entire website for at least 3 months from $49.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
Income statement item | Description | The company |
---|---|---|
Operating income (loss) | The net result for the period of deducting operating expenses from operating revenues. | Bristol-Myers Squibb Co. operating income (loss) as a percentage of revenues decreased from 2019 to 2020 but then increased from 2020 to 2021 not reaching 2019 level. |
Earnings (loss) before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Bristol-Myers Squibb Co. earnings (loss) before income taxes as a percentage of revenues decreased from 2019 to 2020 but then increased from 2020 to 2021 not reaching 2019 level. |
Net earnings (loss) attributable to BMS | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS as a percentage of revenues decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level. |